Replies to post #300 on Aptose Biosciences Inc (APTO)

[dcaf7]

I had no chance to listen to the call yet, but from what I am reading, how it is possible to have a 29% CR/CRh response rate in patients with RAS mutations? You should have 29 responders with RAS mutations out of 100 patients. No more, no less. Have they already enrolled 100 patients?